In this survey we are interested in your opinion on the current and future use of surrogate endpoints in the marketing authorization of drugs. There is much debate regarding the exact definition of terms such as biomarkers and surrogate endpoints. For the purpose of this survey, we have defined surrogate endpoints as biomarkers that function as accepted substitutes for hard clinical endpoints in clinical trials. These biomarkers are accepted as surrogate endpoints because there is regulatory consensus that the biomarker is on the direct causal pathway from disease to hard clinical outcome, as shown in the figure below.
Introduction
First, we would like to know a bit more about your background and your general experience with the use of surrogate endpoints.
1. What is your gender? 2. What is your age? 
Who is your main employer?
FDA n m l k j EMA, or a regulator on a national level within the EU n m l k j Other n m l k j 6. What are your areas of specialization? (providing multiple answers is possible) 7. Have you been professionally involved in the development or marketing authorization of drugs targeted to the following surrogate endpoints?
Yes No
Blood pressure g f e d c g f e d c We continue with questions on the use of surrogate endpoints in marketing authorization.
8. Drug registration based on surrogate endpoints might be beneficial for a wide range of stakeholders in the drug development process. In your opinion, who benefits most from the use of surrogate endpoints? Please use the dropdown menu to rank the groups from most benefit (1) to least benefit (4).
Note: answers change position while indicating your preferences. In the remainder of the survey we are interested in your opinion on the use of surrogate endpoints in the cardiovascular field. The predictive accuracy of surrogate endpoints is being debated in this field due to a number of unexpected results from hard clinical outcome studies. A wellknown example is rosiglitazone that due to its HbA1c lowering effect was expected to decrease the risk of cardiovascular complications in diabetes patients. However, a postmarketing hard clinical outcome study revealed an increase in cardiovascular risk resulting in the withdrawal of the drug from the European market. n m l k j n m l k j n m l k j n m l k j n m l k j
Blood pressurelowering to substitute for EndStage Renal Disease (ESRD) n m l k j n m l k j n m l k j n m l k j n m l k j In current registration practice, many cardiovascular drugs are approved based on efficacy on a single marker (e.g. blood pressure in case of an angiotensin II receptor blocker (ARB) for the treatment of hypertension), to which we will refer in this survey as the ontarget marker. At the same time, these drugs may have an effect on other biomarkers to which we will refer in this survey as offtarget markers. Such offtarget markers can contribute either in a positive (e.g. albuminurialowering effect) way or a negative (e.g. hemoglobinlowering effect) way to a drug's efficacy/safety profile. An example is visualized below, showing how the ARB Losartan has an effect on the ontarget marker blood pressure and the offtarget markers albuminuria, potassium and hemoglobin.
Predictions of longterm treatment effects may be different when taking into account changes in both ontarget and offtarget markers as compared to changes in the ontarget marker alone. To provide insight in these differences, we have developed a novel risk score that predicts the effect of a drug on hard clinical outcomes based on changes in all measured ontarget and offtarget markers.
On the next page, a case will be presented that illustrates the use of the risk score.
Drug effects on multiple biomarkers Background information for the remain...
A drug application was submitted for a novel blood pressurelowering agent called Drug X. Below you will find the most important details of the conducted clinical trials to establish safety and efficacy of Drug X.
The details of 2 registration studies for efficacy: Treatment: Drug X versus placebo Duration: 12 weeks Study population: 900 hypertensive patients drawn from the general population (450 in each group) Measurements: blood pressure and several additional markers
A one year openlabel study with drug X indicated no suspicion of a detrimental effect on cardiovascular hard clinical outcomes.
These studies showed that drug X was well tolerated and any side effects were similar to existing blood pressure lowering agents.
The effects of drug X on multiple on and offtarget markers are summarized in the table below.
13. Based on the information given above, should this drug be approved for market authorization?
Yes, no postmarketing studies involving hard clinical endpoints are required n m l k j Yes, but postmarketing studies involving hard clinical endpoints are necessary to validate the cardioprotective effect of Drug X n m l k j No, followup studies with hard clinical endpoints are necessary before the drug can be registered n m l k j Given the observed changes in biomarkers, the following predictions were made concerning the treatment effect of Drug X on cardiovascular outcomes (stroke, MI and cardiovasular death), relative to placebo: PREDICTIONS BASED ON BLOOD PRESSURELOWERING EFFECT: 15% reduction in cardiovascular risk (p<0.01, 95% CI: 24% to 9%) PREDICTIONS WITH THE NEWLY DEVELOPED RISK SCORE BASED ON CHANGES IN ALL MEASURED BIOMARKERS: 4% increase in cardiovascular risk (p=0.10, 95% CI: 3% to +11%) 14. Based on the predictions given above, should this drug be approved for market authorization?
Yes, no postmarketing studies involving hard clinical endpoints are required n m l k j Yes, but postmarketing studies involving hard clinical endpoints are necessary to validate the cardioprotective effect of Drug X n m l k j No, followup studies with hard clinical endpoints are necessary before the drug can be registered n m l k j 15. Suppose that the risk score is validated in prospective studies and is accurate in predicting the treatment effect of several drug classes in the cardiovascular field, please indicate to what extent you agree or disagree with the following statements on the use of the presented risk score in drug registration.
Strongly disagree
Disagree Neutral Agree Strongly agree
The score provides more accurate predictions on hard clinical outcomes than changes in single markers alone n m l k j n m l k j n m l k j n m l k j n m l k j
The score may be used to You have completed the survey. We thank you for your cooperation. Should you have any further comments, please let us know by using the text box below.
Comments
Thank you 5 5 6 6
